ArticleCost effectiveness and resource allocation : C/E2026
Prevalence and direct costs of vestibular disease in France - matched case-control study results from the 2022 and 2023 french health data system.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceVestibular dysfunction causes vertigo, dizziness, and imbalance, impairing daily life and leading to substantial healthcare use. Precise prevalence and economic impact remain unclear.
objectiveTo estimate the one-year prevalence and direct healthcare costs of vestibular disorders in France.
designA matched case-control study using the French national health data system covering over 67 million records in 2022.
settingNationwide health insurance data including all public and private healthcare interactions. POPULATION: Adults aged ≥18 years diagnosed or treated for vestibular disease, matched 1:1 with controls by age, sex, comorbidities, region, and deprivation. EXPOSURE: Vestibular disorder diagnosis or treatment in 2022. OUTCOME: Direct healthcare expenditures in 2022 and 2023.
resultsVestibular disorders affected 2.5% of adults (1,279,966 cases). Cases incurred mean costs of €4,233 versus €3,719 in controls in 2023, with an excess of €657 million nationally. CONCLUSIONS AND RELEVANCE: Vestibular disorders are common and associated with significant excess healthcare costs. Standardizing diagnostic and therapeutic pathways may reduce expenditures and improve care quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.